3B BlackBio DX reported contrasting financial results for Q1 FY27, with standalone net profit rising 13% year-on-year to ₹141.1 crore while consolidated net profit declined 29% to ₹89.8 crore. The company's revenue from operations decreased 6% to ₹334.9 crore compared to ₹354.3 crore in the corresponding quarter of FY26. According to the latest financial results approved by the Board of Directors on August 13, 2026, the mixed performance reflects the impact of lower other income and subsidiary performance on consolidated results, despite strong standalone growth.
The diagnostic kits segment continues to be the primary revenue driver, contributing ₹320.6 crore or approximately 96% of total consolidated income. The segment generated a profit before interest and tax of ₹133.2 crore, demonstrating strong operational performance in this core business area. In contrast, the agrochemicals segment reported minimal revenue of ₹14.3 crore against ₹22.7 crore in the same quarter last year, reflecting its seasonal nature and weather-dependent performance, as reported by the company.
Despite revenue challenges, the company demonstrated improved operational efficiency with total expenses contained at ₹264.1 crore compared to ₹309.4 crore in Q1 FY26. A significant improvement came from depreciation and amortization expenses dropping sharply to ₹134.4 crore from ₹389.1 crore in the previous quarter, contributing to better profitability margins. The company's operating profit margin (OPM) compressed to 25.47% in Q1 FY27 from 53.22% in the corresponding quarter of the previous year, as reported by Business Standard.
The company's consolidated total income stood at ₹396.3 crore for the quarter, down from ₹455.8 crore in the corresponding quarter of FY26, primarily driven by lower other income which fell to ₹61.4 crore from ₹101.5 crore in the prior year period. The sharp decline in consolidated other income from ₹101.5 crore to ₹61.4 crore raises questions about the company's ability to sustain profit margins if operational revenues remain flat. The board appointed Sanjay Kasliwal & Associates as cost auditor for FY27 to comply with Section 148 of the Companies Act, 2013, as reported by the company.
